{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-24-000210","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.372738+00:00","generated_at":"2026-05-30T08:48:36.042631+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Neurocrine Q3 INGREZZA sales $613M (+26% YoY); raises FY2024 guidance; $300M buyback","bullets":["INGREZZA net product sales $613M in Q3 2024, up 26% YoY; raised 2024 sales guidance to $2.30-$2.32B.","Total revenues $622.1M (+25% YoY); GAAP EPS $1.24 vs $0.82; Non-GAAP EPS $1.81 vs $1.54.","Board authorized $300M share repurchase plan; intends to enter accelerated share repurchase.","New CEO Kyle W. Gano appointed effective Oct 11, 2024; Phase 2 data for NBI-1117568 triggered $35M milestone.","Terminated licenses for luvadaxistat (CIAS) and NBI-827104; terminations expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-24-000210","json":"https://secwatch.observer/filing/0000914475-24-000210.json","markdown":"https://secwatch.observer/filing/0000914475-24-000210.md","text":"https://secwatch.observer/filing/0000914475-24-000210.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000210/0000914475-24-000210-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000210/nbix-20241030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:48:36.042631+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}